1. Angiotensin II-induced cardiomyocyte hypertrophy: A complex response dependent on intertwined pathways
- Author
-
Marta Consegal, Laura Valls-Lacalle, Antonio Rodríguez-Sinovas, Institut Català de la Salut, [Consegal M, Rodríguez-Sinovas A] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Valls-Lacalle L] Biomaterials for Regenerative Therapies Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
medicine.medical_specialty ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Otros calificadores::Otros calificadores::/inducido químicamente [Otros calificadores] ,hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas peptídicas::angiotensinas::angiotensina II [COMPUESTOS QUÍMICOS Y DROGAS] ,Cardiomyocyte hypertrophy ,Cardiomegaly ,Receptor, Angiotensin, Type 1 ,Internal medicine ,Medicine ,Humans ,Myocytes, Cardiac ,General Environmental Science ,business.industry ,Cardiovascular Diseases::Heart Diseases::Cardiomegaly [DISEASES] ,Angiotensin II ,Endocrinology ,Other subheadings::/pharmacology [Other subheadings] ,lcsh:RC666-701 ,Otros calificadores::/farmacología [Otros calificadores] ,Other subheadings::Other subheadings::/chemically induced [Other subheadings] ,General Earth and Planetary Sciences ,Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Angiotensins::Angiotensin II [CHEMICALS AND DRUGS] ,Cardiology and Cardiovascular Medicine ,business ,enfermedades cardiovasculares::enfermedades cardíacas::cardiomegalia [ENFERMEDADES] - Abstract
Hipertrofia cardiomiocitária Hipertròfia cardiomiocitària Cardiomyocyte hypertrophy This study was supported by the Spanish Ministry of Economy and Competitiveness and Instituto de Salud Carlos III (PI17/01397 and CIBERCV), and cofinanced by the European Regional Development Fund (ERDF, ‘a Way to Build Europe’). Antonio Rodríguez-Sinovas has a consolidated Miguel Servet contract.
- Published
- 2021